Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity

Bispecific antibodies continue to represent a growth area for antibody therapeutics, with roughly a third of molecules in clinical development being T-cell engagers that use an anti-CD3 binding arm. CD3 antibodies possessing cross-reactivity with cynomolgus monkey typically recognize a highly electr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Catherine Y, Ahonen, Cory L, Brown, Michael E, Zhou, Ling, Welin, Martin, Krauland, Eric M, Pejchal, Robert, Widboom, Paul F, Battles, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072072/
https://www.ncbi.nlm.nih.gov/pubmed/36991534
http://dx.doi.org/10.1080/19420862.2023.2189974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072072/
https://www.ncbi.nlm.nih.gov/pubmed/36991534
http://dx.doi.org/10.1080/19420862.2023.2189974

Ejemplares similares